Previous 10 | Next 10 |
Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference PR Newswire EMERYVILLE, Calif. , Nov. 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercial...
2023-11-03 05:31:03 ET Image source: The Motley Fool. Dynavax Technologies (NASDAQ: DVAX) Q3 2023 Earnings Call Nov 02, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: Dynavax Technologies (DVAX) Q3 2023 Earnings Call Tr...
2023-11-02 19:07:08 ET Start Time: 16:30 End Time: 16:59 Dynavax Technologies Corporation (DVAX) Q3 2023 Earnings Conference Call November 02, 2023, 16:30 PM ET Company Participants Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Janssen - C...
2023-11-02 16:20:57 ET More on Dynavax Dynavax: Analyzing Mixed Signals, A Closer Look At Heplisav-B Dynavax: Dizzy Optimism Followed -97% Q2 Net Income Decline Seeking Alpha’s Quant Rating on Dynavax Historical earnings data for Dynavax Financ...
Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance PR Newswire Generated quarterly HEPLISAV-B ® vaccine net product revenue of $62.3 million , a 66% year-over-year increase Raising full year HEPLISAV-B net prod...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Dynavax Technologies Corporation (DVAX) is expected to report $-0.01 for Q3 2023
Dynavax to Report Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023 PR Newswire EMERYVILLE, Calif. , Oct. 26, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company de...
2023-10-24 03:04:23 ET Summary Dynavax's HEPLISAV-B Q2 sales surged by 73%, prompting raised full-year guidance. Strong liquidity with $681.5M in liquid assets and positive monthly net cash flow mitigate immediate financing concerns. Market sentiment is mixed, with moderate ma...
Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference PR Newswire EMERYVILLE, Calif. , Oct. 19, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and ...
News, Short Squeeze, Breakout and More Instantly...
Dynavax Technologies Corporation Company Name:
DVAX Stock Symbol:
NASDAQ Market:
Dynavax Technologies Corporation Website:
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 PR Newswire EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company dev...
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program PR Newswire EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing inn...
2024-06-21 02:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...